Antiviral therapy of chronic hepatitis B: past, present, and future (Q40915924)

24 September 2017

1 reference

title

Antiviral therapy of chronic hepatitis B: past, present, and future (English)

1 reference

24 September 2017

1 reference

Perrillo RP

1

1 reference

24 September 2017

publication date

1 January 1993

1 reference

24 September 2017

published in

Journal of Hepatology

1 reference

24 September 2017

volume

17 Suppl 3

1 reference

24 September 2017

page(s)

S56-63

1 reference

Contrasting features and responses to treatment of severe chronic active liver disease with and without hepatitis BS antigen

24 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2805%2980425-8

7 January 2021

Deleterious effect of prednisolone in HBsAg-positive chronic active hepatitis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2805%2980425-8

7 January 2021

Serum levels of hepatitis B surface and core antigens during immunosuppressive treatment of HBsAg-positive chronic active hepatitis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2805%2980425-8

7 January 2021

Quantitation of hepatitis B viral DNA by solution hybridization: comparison with DNA polymerase and hepatitis B e antigen during antiviral therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2805%2980425-8

7 January 2021

A randomized, controlled trial of interferon alfa-2b alone and after prednisone withdrawal for the treatment of chronic hepatitis B. The Hepatitis Interventional Therapy Group

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2805%2980425-8

7 January 2021

Histological improvement after anti-viral treatment for chronic hepatitis B virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2805%2980425-8

7 January 2021

Hepatitis B virus deoxyribonucleic acid in liver of chronic carriers. Correlation with serum markers and changes associated with loss of hepatitis B e antigen after antiviral therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2805%2980425-8

7 January 2021

Interferon alfa therapy in patients with chronic hepatitis B virus infection. Effects on hepatitis B virus DNA in the liver

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2805%2980425-8

7 January 2021

Beta- and gamma-interferon in chronic active hepatitis B. A pilot trial of short-term combination therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2805%2980425-8

7 January 2021

Integration of hepatitis B virus DNA into the genome of liver cells in chronic liver disease and hepatocellular carcinoma. Studies in percutaneous liver biopsies and post-mortem tissue specimens

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2805%2980425-8

7 January 2021

Effect of human leukocyte interferon on hepatitis B virus infection in patients with chronic active hepatitis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2805%2980425-8

7 January 2021

Comparative efficacy of adenine arabinoside 5' monophosphate and prednisone withdrawal followed by adenine arabinoside 5' monophosphate in the treatment of chronic active hepatitis type B.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2805%2980425-8

7 January 2021

A pilot study of BW A515U (6-deoxyacyclovir) in chronic hepatitis B virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2805%2980425-8

7 January 2021

Controlled clinical trial of acyclovir in chronic hepatitis B virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2805%2980425-8

7 January 2021

Inhibition of duck hepatitis B virus replication by 2',3'-dideoxycytidine. A potent inhibitor of reverse transcriptase

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2805%2980425-8

7 January 2021

In vitro and in vivo comparison of the abilities of purine and pyrimidine 2',3'-dideoxynucleosides to inhibit duck hepadnavirus

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2805%2980425-8

7 January 2021

Interferon in viral hepatitis: role in pathogenesis and treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2805%2980425-8

7 January 2021

Randomized, controlled trial of recombinant human alpha-interferon in patients with chronic hepatitis B

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2805%2980425-8

7 January 2021

Recombinant interferon alfa-2b following prednisone withdrawal in the treatment of chronic type B hepatitis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2805%2980425-8

7 January 2021

Prednisone withdrawal followed by recombinant alpha interferon in the treatment of chronic type B hepatitis. A randomized, controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2805%2980425-8

7 January 2021

Long-term remission of chronic hepatitis B after alpha-interferon therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2805%2980425-8

7 January 2021

Anti-HBs response in seroconverting chronic HBV carriers following alpha-interferon treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2805%2980425-8

7 January 2021

Hepatic histologic and immunohistochemical changes in chronic hepatitis B after prolonged clearance of hepatitis B e antigen and hepatitis B surface antigen

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2805%2980425-8

7 January 2021

Side effects of alpha interferon

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2805%2980425-8

7 January 2021

Autoimmune chronic hepatitis exacerbated by alpha-interferon

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2805%2980425-8

7 January 2021

PRIMARY HYPOTHYROIDISM ASSOCIATED WITH INTERFERON THERAPY OF BREAST CANCER

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2805%2980425-8

7 January 2021

Autoimmunity after alpha-interferon therapy for malignant carcinoid tumors

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2805%2980425-8

7 January 2021

Treatment of chronic type B hepatitis with recombinant alpha-interferon induces autoantibodies not specific for autoimmune chronic hepatitis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2805%2980425-8

7 January 2021

Interferon antibodies in patients with chronic HBV infection treated with recombinant interferon

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2805%2980425-8

7 January 2021

Treatment of chronic hepatitis C with recombinant interferon alfa. A multicenter randomized, controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2805%2980425-8

7 January 2021

Interferon antibodies may negate the antiviral effects of recombinant alpha-interferon treatment in patients with chronic hepatitis B virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2805%2980425-8

7 January 2021

Antiviral Treatment of Chronic Hepatitis B Virus Infection. I. Changes in Viral Markers with Interferon Combined with Adenine Arabinoside

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2805%2980425-8

7 January 2021

Alpha-interferon treatment in Chinese patients with chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2805%2980425-8

7 January 2021

Diminished responsiveness of homosexual men to antiviral therapy for HBsAg-positive chronic liver disease

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2805%2980425-8

7 January 2021

Diminished responsiveness of male homosexual chronic hepatitis B virus carriers with HTLV-III antibodies to recombinant alpha-interferon

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2805%2980425-8

7 January 2021

Adenine arabinoside monophosphate (vidarabine phosphate) in combination with human leukocyte interferon in the treatment of chronic hepatitis B. A randomized, double-blinded, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2805%2980425-8

7 January 2021

Combination of short-term prednisolone and adenine arabinoside in the treatment of chronic hepatitis B. A controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2805%2980425-8

7 January 2021

Recombinant leukocyte a interferon treatment in patients with chronic hepatitis B virus infection. Pharmacokinetics, tolerance, and biologic effects

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2805%2980425-8

7 January 2021

Efficacy of interferon alfa-2b with or without prednisone withdrawal in the treatment of chronic viral hepatitis B. A prospective double-blind Belgian-Dutch study

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2805%2980425-8

7 January 2021

Short-term prednisolone followed by recombinant human alpha-interferon alone or combined with adenine-arabinoside in chronic hepatitis B. A prospective and randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2805%2980425-8

7 January 2021

Thymosin treatment of chronic hepatitis B: a placebo-controlled pilot trial

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2805%2980425-8

7 January 2021

Trial of ribavirin for the treatment of HBsAg positive chronic liver disease

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2805%2980425-8

7 January 2021

Natural course and response to interferon of chronic hepatitis B accompanied by antibody to hepatitis B e antigen

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2805%2980425-8

7 January 2021

Interferon alfa-2b treatment of HBeAg negative/serum HBV DNA positive chronic active hepatitis type B

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2805%2980425-8

7 January 2021

PLACEBO-CONTROLLED TRIAL OF RECOMBINANT α2-INTERFERON IN CHINESE HBsAg-CARRIER CHILDREN

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2805%2980425-8

7 January 2021

Prospective, randomized controlled trial of interferon-alpha in children with chronic hepatitis B

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2805%2980425-8

7 January 2021

Improvement of proteinuria in a case of hepatitis B-associated glomerulonephritis after treatment with interferon

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2805%2980425-8

7 January 2021

Preliminary observation of hepatitis B-associated membranous glomerulonephritis treated with leukocyte interferon

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2805%2980425-8

7 January 2021

Glomerulonephritis caused by chronic hepatitis B virus infection: treatment with recombinant human alpha-interferon

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2805%2980425-8

7 January 2021

Zidovudine in asymptomatic human immunodeficiency virus infection. A controlled trial in persons with fewer than 500 CD4-positive cells per cubic millimeter. The AIDS Clinical Trials Group of the National Institute of Allergy and Infectious Diseases

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2805%2980425-8

7 January 2021

10.1016/S0168-8278(05)80425-8

Identifiers

DOI

1 reference

24 September 2017

1 reference